658 related articles for article (PubMed ID: 16809810)
1. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
2. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
3. In vitro galantamine-memantine co-application: mechanism of beneficial action.
Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
[TBL] [Abstract][Full Text] [Related]
4. [Mechanisms of action of Alzheimer medications].
Alhainen K
Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
[No Abstract] [Full Text] [Related]
5. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons.
Aracava Y; Pereira EF; Maelicke A; Albuquerque EX
J Pharmacol Exp Ther; 2005 Mar; 312(3):1195-205. PubMed ID: 15522999
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
7. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
8. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
9. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Crutchfield D
Director; 2008; 16(1):19-21. PubMed ID: 19343870
[TBL] [Abstract][Full Text] [Related]
10. Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice.
Unger C; Svedberg MM; Yu WF; Hedberg MM; Nordberg A
J Pharmacol Exp Ther; 2006 Apr; 317(1):30-6. PubMed ID: 16354790
[TBL] [Abstract][Full Text] [Related]
11. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.
Giorgetti M; Gibbons JA; Bernales S; Alfaro IE; Drieu La Rochelle C; Cremers T; Altar CA; Wronski R; Hutter-Paier B; Protter AA
J Pharmacol Exp Ther; 2010 Jun; 333(3):748-57. PubMed ID: 20194526
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
14. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
15. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
18. [New therapeutic options in Alzheimer's disease].
García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
[TBL] [Abstract][Full Text] [Related]
19. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil.
Woodruff-Pak DS; Tobia MJ; Jiao X; Beck KD; Servatius RJ
Neuropsychopharmacology; 2007 Jun; 32(6):1284-94. PubMed ID: 17119537
[TBL] [Abstract][Full Text] [Related]
20. Drugs for Alzheimer's disease.
Cranwell-Bruce LA
Medsurg Nurs; 2010; 19(1):51-3. PubMed ID: 20336985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
